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Abstract
A preclinical murine model of hydroxyapatite (HA) breast microcalcifications (µcals), which are 
an important clinical biomarker for breast cancer detection, was used to investigate the 
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independent effects of high affinity bisphosphonate (BP) ligands and a polyethylene glycol 
(PEG) spacer on targeted delivery of gold nanoparticles (Au NPs) for contrast-enhanced 
radiographic detection. The addition of BP ligands to PEGylated Au NPs (BP-PEG-Au NPs) 
resulted in five-fold greater binding affinity for targeting HA µcals, as expected, due to the 
strong binding affinity of BP ligands for calcium. Therefore, BP-PEG-Au NPs were able to 
target HA µcals in vivo after intramammary delivery, which enabled contrast-enhanced 
radiographic detection of µcals in both normal and radiographically dense mammary tissues 
similar to previous results for BP-Au NPs, while PEG-Au NPs did not. The addition of a PEG 
spacer between the BP targeting ligand and Au NP surface enabled improved in vivo clearance. 
PEG-Au NPs and BP-PEG-Au NPs were cleared from all mammary glands (MGs) and control 
MGs, respectively, within 24-48 h after intramammary delivery, while BP-Au NPs were not. 
PEGylated Au NPs were slowly cleared from MGs by lymphatic drainage and accumulated in 
the spleen. Histopathology revealed uptake of PEG-Au NPs and BP-PEG-Au NPs by 
macrophages in the spleen, liver, and MGs; there was no evidence of toxicity due to the 
accumulation of NPs in organs and tissues compared with untreated controls for up to 28 days 
after delivery.
Statement of Significance
Au NP imaging probes and therapeutics are commonly surface functionalized with PEG and/or 
high affinity targeting ligands for delivery. However, direct comparisons of PEGylated Au NPs 
with and without a targeting ligand, or ligand-targeted Au NPs with and without a PEG spacer, 
on in vivo targeting efficiency, biodistribution, and clearance are limited. Therefore, the results 
of this study are important for the rationale design of targeted NP imaging probes and 
therapeutics, including the translation of BP-PEG-Au NPs which enable improved sensitivity and 
  
specificity for the radiographic detection of abnormalities (e.g., µcals) in women with dense 
breast tissue.
1. Introduction
Breast cancer is the most common cancer and the second leading cause of cancer-related 
deaths among women in the United States [1]. The five-year survival rate is 98.6% when 
diagnosed while still confined to the breast, but only 23.3% when diagnosed after metastasizing 
to distant sites [2]. Therefore, early detection and correct diagnosis of breast cancer is critical for 
patient survival. Mammographic screening of women ages 40-69 has been associated with a 
20-40% reduction in mortality across numerous studies [3,4]. At the same time, mammographic 
screening can result in false-positives, unnecessary biopsies, and overdiagnosis [3,4].
Both the sensitivity and specificity of mammography are dramatically decreased with 
increased breast density [4,5]. Elevated breast density is an independent risk factor for breast 
cancer and the risk is greatest during the first 12 months following a mammogram, which 
suggests that this risk results from impaired detection of abnormalities (e.g., microcalcifications) 
that are masked in mammography by the elevated tissue density [6]. Thus, new imaging methods 
are needed to improve breast cancer detection in women with elevated radiographic breast 
density [6].
Ultrasound, magnetic resonance imaging (MRI), and molecular breast imaging (MBI) 
have been investigated as an adjunct to mammography to improve the detection of abnormalities 
in women with dense breast tissue [7-9]. However, these methods each have their own 
limitations in sensitivity, specificity, spatial resolution, radiation dose, availability, cost, and 
other barriers to widespread adoption [7-9]. Contrast-enhanced dual-energy mammography, 
which utilizes conventional mammography and iodinated contrast agents to distinguish tumors 
  
via vascularity, was recently demonstrated to exhibit detection rates comparable to MRI [10,11]. 
However, iodinated molecules are limited by potential allergic reactions in patients, rapid 
clearance, and suboptimal X-ray attenuation, which has motivated investigation of targeted 
nanoparticle contrast agents for CT [12-16] including optimal compositions for dual-energy 
mammography [17]. Targeted contrast agents that improve the sensitivity and specificity of 
existing mammographic instrumentation and screening practices could mitigate the need for 
adjunct imaging modalities and promote clinical adoption.
Bisphosphonate-functionalized gold nanoparticles (BP-Au NPs) were recently shown to 
enable improved sensitivity and specificity for contrast-enhanced radiographic detection of 
breast microcalcifications (µcals) in murine models of normal and radiographically dense 
mammary tissue [18-20]. µcals are an important early marker for breast cancer and the most 
common abnormality detected by mammographic screening [21-23]. Targeted delivery of BP-Au 
NPs to µcals was facilitated by BP ligands, which exhibit high binding affinity for 
hydroxyapatite (HA) [24], the mineral component of µcals associated with malignant breast 
lesions [22].
Au NPs are advantageous as an X-ray contrast agent due to exhibiting strong X-ray 
attenuation, low cytotoxicity in vivo, and facile surface functionalization for colloidal stability 
and molecular targeting [25,26]. Polyethylene glycol (PEG) is commonly used to stabilize Au 
NPs for improved blood pool stability and circulation upon in vivo delivery [25-28]. The 
importance of high binding affinity ligands for targeted delivery of Au NPs is well-established 
[25], but the independent effects of a PEG spacer and targeting ligand are not well understood 
[28]. Direct comparisons of PEGylated Au NPs with and without a targeting ligand, or ligand-
targeted Au NPs with and without a PEG spacer, on in vivo targeting efficiency, biodistribution, 
  
and clearance are lacking. Previous preclinical studies have primarily focused on demonstrating 
feasibility of targeted delivery to biological targets (e.g., tumors, lymph nodes, brain, etc.) [12-
15]. These models are clinically significant but exhibit inherent biological variability in the target 
that complicates efforts to study the independent effects of a PEG spacer and targeting ligand on 
the targeting efficiency and clearance.
Therefore, the objective of this study was to investigate the effects of BP ligands on 
targeted delivery of PEGylated Au NPs in a murine model for contrast-enhanced radiographic 
detection of breast µcals. The murine µcal model affords relatively precise control and low 
variability of the engineered µcal targets compared with other in vivo models that utilize 
biologically-derived targets, and was previously used to investigate BP-Au NPs without a PEG 
spacer [19,20]. Therefore, PEGylated Au NPs with (BP-PEG Au NPs) and without (PEG-Au 
NPs) a BP targeting ligand, and BP-functionalized Au NPs with (BP-PEG Au NPs) and without 
(BP-Au NPs) a PEG spacer, were able to be directly compared in a well-characterized and 
highly-controllable preclinical model. We hypothesized that targeting and contrast-enhanced 
detection of µcals using BP-PEG-Au NPs would be compromised by the absence of a BP 
targeting ligand. Previous investigations of contrast-enhanced radiographic detection of breast 
µcals using BP-Au NPs [18-20] did not utilize a PEG spacer; therefore, we also hypothesized 
that incorporating a PEG spacer between the Au NP surface and BP targeting ligand would 
improve biostability and mammary gland clearance compared with BP-Au NPs.
2. Materials and methods
2.1. Synthesis of PEG-Au NPs and BP-PEG-Au NPs
Au NPs were synthesized with a mean NP diameter of ~13 nm and gold concentration of 
~0.5 mM in aqueous solution using the citrate reduction method as previously described in detail 
  
[29-31]. Au NPs were PEGylated by adding either a monofunctional thiol-PEG (SH-PEG, 
CH3O(CH2CH2O)nCH2CH2SH, 2000 Da, Sigma-Aldrich, St. Louis, MO) or heterobifunctional 
thiol-PEG-carboxylic acid (SH-PEG-COOH, CHO2(CH2CH2O)nCH2CH2SH, 2000 Da, Creative 
PEGWorks, Winston Salem, NC) to as-synthesized Au NPs at a PEG/Au molar ratio of 0.1 and 
stirring overnight to allow covalent Au-thiol bonding. BP targeting ligands were added to 
COOH-PEG-Au NPs by mixing ~20 mg N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (EDC, C8H17N3·HCl, 99.0%, Sigma-Aldrich) and ~20 mg N-
hydroxysulfosuccinimide sodium salt (NHS, C4H4NNaO6S, 98%, Sigma-Aldrich) with 30 mL of 
COOH-PEG-Au NPs at 0.5 mM Au concentration buffered with 0.01 M 2-(N-
morpholino)ethanesulfonic acid (MES, 99%, C6H13NO4S, Sigma-Aldrich) under stirring for 
25 min. Activated COOH-PEG-Au NPs were collected and separated from unreacted EDC and 
NHS by centrifugation (Sorvall RD 6 Plus, Thermo Scientific Corporation, Waltham, MA) at 
1485g for 30 min using molecular weight cutoff filters (Amicon Ultra-15 10k, Millipore 
Corporation, Billerica, MA). Activated COOH-PEG-Au NPs were resuspended in phosphate 
buffered saline (PBS, Amresco, Solon, OH) to 30 mL, 10 mg alendronate sodium trihydrate 
(C4H12NaNO7P2·3H2O, ≥97%, Sigma-Aldrich) was added, and the solution was stirred 
overnight. All solutions of PEG-Au NPs and BP-PEG-Au NPs were washed thrice by 
centrifugation at 16,770g for 1 h to remove excess PEG and BP prior to further use.
2.2. Characterization
The particle diameter, hydrodynamic diameter, zeta potential, colloidal stability in 
physiological media, and surface density of PEG and BP were characterized for PEG-Au NPs 
and BP-PEG-Au NPs. Results were compared to BP-Au NPs and as-prepared, citrate-stabilized 
Au NPs which were previously prepared and characterized using identical methods [30-32]. The 
  
particle diameter distribution was measured from a total of at least 100 randomly selected 
particles using transmission electron microscopy (TEM, FEI Titan 80-300, Hillsboro, OR) at 
80 kV accelerating voltage. TEM specimens were prepared by evaporating drops pipetted from 
NP solutions onto carbon-coated grids. The hydrodynamic diameter and zeta potential were 
measured for three replicates of three samples at ambient temperature using dynamic light 
scattering (DLS, Zetasizer Nano ZS90, Malvern Instruments, Worcestershire, UK) after diluting 
as-prepared NPs to a final gold concentration of ~0.5 μM in water, which was buffered with 
10 mM NaCl (pH 7.2) for zeta potential. Colloidal stability in physiological media was 
characterized by both DLS and UV-vis spectroscopy (Nanodrop 200C, Thermo Scientific, 
Wilmington, DE) after diluting NP solutions with an equal volume of either deionized (DI) 
water, PBS, or 10% fetal bovine serum (FBS, Omega Scientific, Tarzana, CA) in PBS to a final 
gold concentration of ~40 mg/L. The hydrodynamic diameter and surface plasmon resonance 
(SPR) were measured at 0, 2, and 7 days following dilution.
The number of PEG molecules absorbed to Au NP surfaces (PEG/Au NP) was measured 
for three samples using thermogravimetric analysis (TGA, TGA/DCS-1, Mettler Toledo, 
Columbus, OH), heating 2-5 mg lyophilized samples of PEG-Au NPs and BP-PEG-Au NPs from 
10 to 800°C at 10°C/min under nitrogen atmosphere flowing at 50 ml/min. The number of BP 
molecules per Au NP (BP/Au NP) and NP surface area (BP/nm2) was calculated from the 
measured mass ratio of elemental P:Au and particle size distributions, using methods previously 
described in detail [30]. Assumptions included prolate spheroids for NPs, a P:BP molar ratio of 
2:1, and a bulk density of gold of 19.3 g/cm3. The mass ratio of elemental P:Au was measured 
for three samples using inductively coupled plasma-optical emission spectroscopy (ICP-OES, 
Optima 8000, Perkin Elmer, Inc. Waltham, MA) after digesting solutions with 3% v/v aqua regia 
  
(3:1 HCl:HNO3). Calibration curves for ICP-OES were created by diluting certified standard P 
and Au solutions (Assurance grade, SPEX CertiPrep, Metuchen, NJ).
2.3. Binding affinity to HA
The binding of PEG-Au NPs and BP-PEG-Au NPs to HA crystals was measured in DI 
water using previously established methods, such that results were compared to previously 
reported results for BP-Au NPs and Au NPs [30]. Briefly, whisker-shaped HA crystals 
(10 ± 0.1 mg), exhibiting a mean length and width of ~18 × ~2 µm [33], and varying 
concentrations of PEG-Au NPs or BP-PEG-Au NPs were added to DI water for a total volume of 
15 mL, placed onto a test tube rotator, and allowed to incubate for 4 h. HA crystals with bound 
Au NPs were separated from unbound Au NPs remaining in solution by centrifugation at ~700g 
for 2 min. The Au concentration in control (no HA crystals) and supernatant solutions was 
measured by ICP-OES (Optima 8000, PerkinElmer) using the methods described above. All 
binding tests were performed in triplicate.
Binding isotherms were plotted as the mass of Au NPs bound per mass of HA crystals, V 
(mg Au/g HA), versus the initial Au concentration, [S] (mg Au/L). Binding isotherms were 
modeled as a Langmuir isotherm,
where V is the mass of Au NPs bound per mass of HA crystals (mg/g), Vmax is the maximum 
surface binding (mg/g), [S] is the initial concentration of gold (mg/L), and K is the equilibrium 
binding constant (mg/L). K and Vmax were determined using non-linear least squares regression 
(JMP 13, SAS Institute, Inc., Cary, NC). Vmax was also normalized to the specific surface area of 
HA crystals, Vmax* (mg Au/m2 HA), and calculated as the maximum number of Au NPs bound 
𝑉 = 𝑉𝑚𝑎𝑥[𝑆]𝐾 + [𝑆] (1)
  
per surface area of HA crystals, Vmax# (#/µm2 HA). The specific surface area of the HA crystals 
was previously measured to be 5.63 m2/g [30]; the number of Au NPs was estimated from the 
bulk density of gold (19.3 g/cm3) and the measured mean particle size.
Binding of PEG-Au NPs and BP-PEG-Au NPs to HA crystal surfaces was also verified 
by field emission scanning electron microscopy (FE-SEM, 400 XHR, FEI, Hillsboro, OR) at an 
accelerating voltage of 5.0 kV and current of 6.3 pA. Samples were prepared by drying collected 
HA crystals at 50°C, redispersing in 90% ethanol, pipetting drops onto heated SEM stubs to 
quickly evaporate the solvent, and coating with 2.5 nm iridium by sputter deposition.
2.4. Murine model of µcals within radiographically dense mammary tissue.
Radiographic detection of µcals was investigated using a previously established 
transgenic murine model of premalignant breast cancer which recapitulates radiographically 
dense mammary tissue [20] in combination with previously established methods for creating 
breast µcals of controlled size within murine mammary glands (MGs) [18-20]. Results were 
compared to previously reported results for BP-Au NPs using identical models [20]. Female 
mice positive for the mouse mammary tumor virus-polyoma middle T-antigen (MMTV-PyMT or 
PyMT) transgene and female wildtype mice negative for the PyMT transgene were obtained by 
breeding male PyMT mice (Jackson Laboratory, Bar Harbor, ME) on a FVB/NJ background 
with female FVB mice (Jackson Laboratory) lacking the PyMT transgene. All mice were 
genotyped for the PyMT transgene using polymerase chain reaction with DNA extracted from 
ear biopsies at 3 weeks of age. At 7-8 weeks of age, µcals were created within normal and 
radiographically dense mammary tissue in wildtype and PyMT mice (n = 5/group), respectively, 
by injecting the left number 4 (4L) MG of anesthetized mice with 50 µL Matrigel (BD 
Biosciences, San Jose, CA) containing 5.0 mg/mL HA crystals. Matrigel alone was injected into 
  
the right number 4 (4R) MG as a negative, contralateral control. All procedures were approved 
by the Institutional Animal Care and Use Committee at the University of Notre Dame and were 
conducted in accordance with the guidelines of the U.S. Public Health Service Policy for 
Humane Care and Use of Laboratory Animals.
2.5. Contrast-enhanced CT
PEG-Au NPs or BP-PEG-Au NPs were administered to anesthetized mice 24 h after 
creating µcals by intramammary injection of a 100 µL dose containing 50 mM Au NPs, which 
corresponded to 2 mg Au/mouse, into both the 4L and 4R MG. Mice were imaged in vivo under 
anesthesia by computed tomography (CT, Albira, Bruker Corporation, Billerica, MA) 
immediately prior to delivering Au NPs (0 h) and longitudinally at 3, 6, 24, and 48 h after 
delivering Au NPs (n = 5/group/time point). CT images were acquired at 45 kVp and 400 µA for 
600 slices with a 250 ms integration time, 125 µm voxel size, and a 0.5 mm aluminum filter. 
Three-dimensional (3D) CT reconstructions were analyzed using PMOD (v3.17, PMOD 
Technologies Ltd., Zurich, Switzerland). X-ray attenuation was measured within an animal-
specific volume of interest (VOI) determined by contrast between the µcal and surrounding 
mammary tissue prior to delivery of Au NPs and subsequently mapped onto CT images acquired 
longitudinally after delivery of Au NPs. The pooled mean (± standard deviation) VOI was 14.3 
(0.92) mm3. Measured grayscale intensities were converted to Hounsfield units (HU) by 
calibration with air (-1000 HU) and water (0 HU). Two-dimensional (2D) projections of 3D CT 
reconstructions were created for visualization using VolView (v3.4, Kitware Inc., Clifton Park, 
NY).
2.6. Biodistribution and histology
  
Wildtype mice were euthanized at 2, 14, and 28 days after delivery of Au NPs, while 
PyMT mice were euthanized 2 and 14 days after delivery of Au NPs (n = 5/group/time point). 
Note that PyMT mice were not permitted to live more than 14 days after delivery of Au NPs (9-
10 weeks of age) due to the development of palpable tumors after this time point and the overall 
tumor burden on mice by 11-12 weeks of age. Selected organs (liver, spleen, kidney, lung, heart, 
brain, intestine, and skin), tissues (MGs, femora, and peritoneum), and µcals were dissected from 
three mice in each group, dried overnight in an oven at 37°C, massed, and digested in aqua regia 
(3 HCl:1 HNO3) for 24 h. The mass of Au in each sample and mass of Ca in µcals was measured 
using ICP-OES (Optima 8000, Perkin Elmer). Calibration curves were created by diluting 
certified standard Au and Ca solutions (SPEX CertiPrep). In remaining mice, freshly dissected 
MGs were immediately fixed in ice cold 4% paraformaldehyde (PFA) for 2 h, while livers and 
spleens were fixed in neutral buffered formalin for 24 h at room temperature. All tissues were 
then rinsed with PBS, dehydrated in a graded series of ethanol solutions, embedded in paraffin, 
sectioned to 4 µm, and stained with hematoxylin and eosin. Stained tissue sections were imaged 
by transmitted light microscopy (Eclipse ME600, Nikon Instruments, Melville, NY) at 1000X 
magnification and interpreted by a medical pathologist.
2.7. Statistical methods
All measurements of replicates were reported as the mean (± standard deviation). 
Differences in the measured NP diameter, hydrodynamic diameter, zeta potential, PEG/Au NP, 
and BP/Au NP were examined using one-way analysis of variance (JMP 13, SAS Institute Inc., 
Cary, NC) and post hoc comparisons were performed using Tukey’s HSD tests. Differences in 
the hydrodynamic diameter in various physiological media over time were examined using 
repeated measures ANOVA and post hoc comparisons were performed using Tukey’s HSD tests. 
  
A log-transform of the hydrodynamic diameter was used to provide a normal distribution for 
analysis. Differences in X-ray attenuation between experimental groups and time points were 
examined using a mixed model analysis of variance (ANOVA) accounting for longitudinal 
repeated measures and the nested, random effect of the animal. Post hoc comparisons between 
µcals and negative controls within wildtype and PyMT mice, both before and after delivering 
PEG-Au NPs or BP-PEG Au NPs, were performed using a paired t-test at each longitudinal time 
point. Post hoc comparisons between the X-ray attenuation measured before delivering Au NPs 
and at longitudinal time points after delivering Au NPs, for both µcals and negative controls 
within wildtype and PyMT mice, were performed using Tukey’s HSD tests. The level of 
significance for all tests was set at p < 0.05.
3. Results and discussion
3.1. Physicochemical characterization
Au NPs were synthesized using the citrate reduction method and surface functionalized 
with either monofunctional thiol-terminated PEG (PEG-Au NPs, Fig. 1a) or heterobifunctional 
thiol- and carboxyl-terminated PEG, which was conjugated to alendronate, a BP with a primary 
amine, using EDC/NHS chemistry (BP-PEG-Au NPs, Fig. 1b). Resulting PEG-Au NPs and BP-
PEG-Au NPs were spherical and monodispersed, as characterized by TEM (Fig. 1); the 
difference in the mean particle diameter was not statistically significant (Table 1). The 
hydrodynamic diameter distribution measured by DLS was also similar for PEG-Au NPs and 
BP-PEG-Au NPs (Fig. 1), but the mean hydrodynamic diameter was slightly increased with the 
addition of BP ligands (Table 1), as expected. The mean hydrodynamic diameter of BP-Au NPs 
investigated previously was larger still (Table 1), likely due to the presence of weakly associated 
polyvinyl alcohol molecules which were added as a stabilizer during BP surface 
  
functionalization [32]. Importantly, PEG-Au NPs, BP-PEG-Au NPs, and BP-Au NPs exhibited a 
hydrodynamic diameter that was comparable in magnitude and significantly larger than that for 
as-prepared, citrate-stabilized Au NPs (Table 1).
The zeta potential measured by DLS was near neutral for PEG-Au NPs and became more 
negative for BP-PEG-Au NPs due to the charge of BP ligands (Table 1), as expected. The zeta 
potential of BP-PEG-Au NPs was comparable but more negative than BP-Au NPs, most likely 
due to a greater density of conjugated BP ligands (Table 1). Surface functionalization decreased 
the magnitude of the negative zeta potential exhibited by as-prepared, citrate-stabilized Au NPs, 
due to the displacement and removal of citrate ions (Table 1). Thus, measured changes in both 
the hydrodynamic diameter and zeta potential indicated successful surface functionalization of 
the as-prepared Au NPs.
The mean number of PEG molecules adsorbed to Au NP surfaces (PEG/Au NP) was 
~900-1000 and was not different between PEG-Au NPs and BP-PEG-Au NPs (Table 1). The 
measured PEG/Au NP was comparable to previous reported measurements for PEGylated NPs of 
similar size and PEG molecular weight [27,34,35]. The number of BP molecules per Au NP 
(BP/Au NP) and NP surface area (BP/nm2) was ~2500 and 5, respectively, for BP-PEG-Au NPs, 
which was greater than that for BP-Au NPs (Table 1). This difference was most likely due to BP-
PEG-Au NPs allowing BP molecules to directly adsorb onto Au NP surfaces, via the primary 
amine in alendronate, in addition to being conjugated to PEG molecules. In contrast, BP-Au NPs 
only permitted binding of BP molecules directly onto Au NP surfaces via the primary amine in 
alendronate [32]. Therefore, PEGylated Au NPs enabled conjugation of a greater number and 
surface density of BP targeting ligands than was possible by binding BP molecules directly onto 
Au NP surfaces.
  
3.2. Colloidal stability in physiologically relevant media
As-prepared PEG-Au NPs and BP-PEG-Au NPs exhibited colloidal stability in 
physiologically relevant media, including DI water, PBS, and 10% FBS, over a period of 7 days 
as characterized by DLS and UV-vis spectroscopy. The mean hydrodynamic particle diameter 
remained unchanged over 7 days in DI water and PBS for both PEG-Au NPs and BP-PEG-Au 
NPs (Fig. 2). In FBS, the mean hydrodynamic diameter of PEG-Au NPs and BP-PEG-Au NPs 
was significantly increased by day 7 (Fig. 2a) and day 2 (Fig. 2b), respectively. However, the 
characteristic SPR peak remained unchanged over 7 days in DI water, PBS, and FBS for both 
PEG-Au NPs (Fig. 2a) and BP-PEG-Au NPs (Fig. 2b). Therefore, the increase in hydrodynamic 
diameter measured for BP-PEG-Au NPs in FBS at day 2 (Fig. 2a) was most likely due to non-
specific electrostatic adsorption of serum proteins to the negatively-charged BP-PEG-Au NPs 
(Table 1) and was similar to that previously measured for BP-Au NPs under identical conditions 
[32]. Moreover, the further increase in hydrodynamic diameter measured for both PEG-Au NPs 
and BP-PEG-Au NPs in FBS at day 7 was most likely due to coagulation and precipitation of the 
serum proteins. This explanation was further confirmed by measuring the hydrodynamic 
diameter of the 10% FBS media in the absence of NPs, which did not exhibit an increase at day 2 
but exhibited an increase of similar magnitude by day 7 (data not shown).
3.3. Binding affinity to HA
BP-PEG-Au NPs exhibited significantly greater binding affinity to HA crystals compared 
with PEG-Au NPs (Fig. 3, Table 2), as expected, due to the high binding affinity of BP ligands 
chelating calcium ions on HA crystal surfaces [24] compared with a weak, non-specific 
electrostatic interaction between PEG and HA crystal surfaces. The difference in binding affinity 
to HA was visually striking in representative SEM micrographs (Fig. 3). The binding isotherm 
  
for BP-PEG-Au NPs was accurately modeled by a Langmuir isotherm (Fig. 3) with a correlation 
coefficient of 0.95 (Table 2). Maximum surface binding constants (Vmax, Vmax*, and Vmax#) were 
approximately five-fold greater for BP-PEG-Au NPs compared with PEG-Au NPs (Table 2).
The maximum surface binding constants previously measured for BP-Au NPs using 
identical methods [30] were comparable in magnitude but lower than BP-PEG-Au NPs (Table 2). 
Therefore, the addition of a PEG spacer between the BP targeting ligand and Au NP surface, and 
the concomitant increase in BP/Au NP (Table 1), resulted in a greater binding affinity to HA 
surfaces (Table 2). However, the magnitude of the difference in binding affinity was relatively 
small compared with the variability in measurements of BP/Au NP and Vmax. Both BP-PEG-Au 
NPs and BP-Au NPs possessed an excess of high affinity BP ligands for targeting HA.
3.4. Targeted delivery to µcals within mouse MGs
Contrast-enhanced radiographic detection of µcals targeted by BP-PEG Au NPs was 
investigated using a previously established and well-characterized model for creating engineered 
HA µcals within normal (wildtype mice) and radiographically dense (PyMT mice) mammary 
tissue [18-20]. In all wildtype and PyMT mice, model µcals were injected into the fat pad of the 
left number 4 MG while the right number 4 MG served as a negative, contralateral control. Mice 
were imaged by CT after creating µcals but prior to delivering PEG-Au NPs or BP-PEG-Au NPs 
(0 h), and longitudinally at 3, 6, 24, and 48 h after delivering PEG-Au NPs or BP-PEG-Au NPs 
via intramammary injection into both the left and right number 4 MGs.
Prior to delivering PEG-Au NPs or BP-PEG-Au NPs, MGs with µcals exhibited greater 
X-ray attenuation compared with contralateral controls in wildtype mice (Fig. 4a,b), but not in 
PyMT mice (Fig. 4c,d) due to the elevated mammary tissue density of PyMT mice masking the 
detection of µcals [20]. The elevated radiographic density of PyMT mice was previously shown 
  
to be due to hyperplastic epithelium and greater amounts of collagen at a premalignant stage of 
development [20,36,37], which recapitulated elevated radiographic density in human breast 
tissue associated with fibroglandular tissue. Importantly, the addition of engineered µcals within 
wildtype and PyMT mice was further able to recapitulate the clinical challenges of detecting 
small abnormalities in dense breast tissue by radiographic imaging. The murine µcal model 
provided a pathological target with more precise control and lower variability than is possible 
with biologically-derived targets, which is advantageous for investigating contrast-enhanced 
detection of a pathological target.
After delivering PEG-Au NPs, MGs with µcals and contralateral controls, in both 
wildtype and PyMT mice, exhibited a transient increase in X-ray attenuation over 3-6 h and then 
decreased back to initial levels by 24-48 h (Fig. 4a,c), such that the difference in X-ray 
attenuation before and 48 h after delivery of PEG-Au NPs was not statistically significant. 
Moreover, the relative difference in X-ray attenuation (differential contrast, ∆HU) between MGs 
with µcals and contralateral controls in wildtype mice (Fig. 4a), or the lack of a difference in X-
ray attenuation between MGs with µcals and contralateral controls in PyMT mice (Fig. 4c), was 
generally maintained at all time points after delivery of PEG-Au NPs. These results suggest that 
PEG-Au NPs were readily cleared from MGs within 24-48 h after intramammary administration 
and were unable to target HA µcals in vivo due to the lack of high binding affinity ligands. 
Therefore, PEG-Au NPs were unable to enhance the contrast of µcals in either normal or 
radiographically dense mammary tissues.
After delivering BP-PEG-Au NPs, contralateral control MGs in both wildtype and PyMT 
mice also exhibited a transient increase in X-ray attenuation over 6 h, and then decreased back to 
initial levels by 24-48 h (Fig. 4b,d), such that the difference in X-ray attenuation before and 24-
  
48 h after delivery of BP-PEG-Au NPs was not statistically significant. In contrast, MGs with 
µcals in both wildtype and PyMT mice exhibited an increase in X-ray attenuation that was 
maintained at each time point after delivering BP-PEG-Au NPs (Fig. 4b,d), such that the 
difference in X-ray attenuation before and up to 48 h after delivery of BP-PEG-Au NPs was 
statistically significant. Moreover, MGs with µcals exhibited increased X-ray attenuation 
compared with contralateral controls at all time points after delivery of BP-PEG-Au NPs. Thus, 
the relative difference in X-ray attenuation (differential contrast, ∆HU) between MGs with µcals 
and contralateral controls in both wildtype (Fig. 4b) and PyMT (Fig. 4d) mice was increased at 
24-48 h after delivery of BP-PEG-Au NPs compared with before delivery. These results suggest 
that BP-PEG-Au NPs were readily cleared from control MGs within 24-48 h after intramammary 
administration and were able to target HA µcals in vivo due to high binding affinity BP ligands. 
Therefore, BP-PEG-Au NPs enabled contrast-enhanced detection of µcals in both normal and 
radiographically dense mammary tissues. These results also suggest that BP-PEG-Au NPs 
enabled improved specificity for detecting µcals in normal mammary tissues (Fig. 4b) and 
improved sensitivity for detecting µcals that were otherwise undetectable in radiographically 
dense mammary tissues (Fig. 4d).
The ability of BP-PEG-Au NPs to target HA µcals and enhance radiographic contrast was 
not unlike previous results for BP-Au NPs using the same in vivo model [20]. However, BP-
PEG-Au NPs were more readily cleared from control MGs compared with BP-Au NPs. The 
delivery of BP-Au NPs to control MGs resulted in an increase in X-ray attenuation that was 
maintained at each subsequent time point, such that the difference in X-ray attenuation before 
and up to 48 h after delivery of BP-Au NPs was statistically significant [20]. In contrast, the 
delivery of BP-PEG-Au NPs to control MGs resulted in a transient increase in X-ray attenuation 
  
that returned to initial levels by 24-48 h (Fig. 4b,d), such that the difference in X-ray attenuation 
before and 24-48 h after delivery of BP-PEG-Au NPs was not statistically significant. This result 
suggests that the addition of a PEG spacer between the BP targeting ligand and Au NP surface 
enabled improved clearance in vivo.
3.5. Biodistribution and histology
The biodistribution of PEG-Au NPs and BP-PEG-Au NPs in various organs and tissues 
was measured at 2, 14, and 28 days after delivery in wildtype mice, and at 2 days after delivery 
in PyMT mice (Fig. 5). The 14 and 28 day time points were not completed for PyMT mice due to 
the development of nonpalpable tumors by 14 days after delivery of Au NPs (9-10 weeks of age) 
and the overall tumor burden on mice by 11-12 weeks of age. The highest concentrations of Au 
were measured in µcals, MGs, the surrounding skin, and peritoneum at every time point for both 
PEG-Au NPs and BP-PEG-Au NPs in both WT and PyMT mice (Fig. 5). The relatively high 
concentration of Au at these sites was expected due to the localized, intramammary 
administration of Au NPs. The concentration of Au in µcals was greater for BP-PEG-Au NPs 
(Fig. 5b) compared with PEG-Au NPs (Fig. 5a), and was maintained over 28 days, confirming 
targeting of HA µcals by BP-PEG-Au NPs. Thus, important trends observed in X-ray attenuation 
measurements at the 48 h time point (Fig. 4) were in good agreement with the measured Au 
biodistribution at the same time point (Fig. 5). This suggests that CT can be used to non-
invasively measure the in vivo biodistribution of NPs, especially with the advent of photon-
counting spectral CT enabling k-edge imaging [40].
The concentration of Au in MGs and the surrounding skin and peritoneum exhibited little 
change over 28 days (Fig. 5). Interestingly, the concentration of Au increased over time in the 
spleen (Fig. 5), while concentrations of Au measured in the liver, kidneys, lungs, heart, brain, 
  
intestines, and femora were low, often within the measurement noise. These results suggest that 
after intramammary administration, Au NPs were slowly cleared from MGs by lymphatic 
drainage and accumulated in the spleen. In contrast, there was relatively little or no clearance 
from MGs to the liver and kidneys, as is commonly observed after intravenous delivery 
[25,27,41-43]. Thus, the route of administration had a profound effect on the in vivo 
biodistribution of PEGylated Au NPs.
The biodistribution previously measured for BP-Au NPs using the same in vivo model 
and characterization methods revealed comparable concentrations of Au in the MGs and the 
surrounding skin and peritoneum, but much lower accumulation in the spleen [20]. Thus, PEG-
Au NPs and BP-PEG-Au NPs were more readily cleared from MGs and surrounding tissues to 
the spleen compared with BP-Au NPs. This result suggests that the addition of a PEG spacer 
between the BP targeting ligand and Au NP surface enabled improved clearance from MGs in 
vivo.
Lymphatic clearance of NPs has been previously reported after subcutaneous delivery 
[44-47], which could be expected to exhibit a similar clearance route as intramammary delivery. 
Inguinal lymph nodes in the number 4 MGs were visually observed to be dark red in color upon 
dissection of the MGs. This observation suggests that after intramammary delivery PEGylated 
Au NPs were transported to the resident lymph nodes [48]. However, the concentration of Au in 
the lymph nodes over time was not measured separately from the entire MG due to the small 
mass of tissue. Transport of PEGylated Au NPs from resident lymph nodes to the spleen 
occurred via slow drainage from lymphatic vessels into the blood pool which is filtered by the 
spleen [49]. PEGylated Au NPs accumulated in the spleen (Fig. 5), where they were taken up by 
splenic macrophages (Fig. 6) [49,50]. The mechanism for accumulation of PEGylated Au NPs in 
  
the spleen after intramammary delivery vs. the liver and kidneys after intravenous delivery is not 
entirely clear. One possible explanation is that PEGylated Au NPs are opsonized by antibodies in 
the lymph fluid which are recognized by the spleen, but the role of the spleen in the 
pharmacokinetics of NPs is not yet well-understood [49].
The total amount of Au (mg) measured in all the organs and tissues did not change with 
time (data not shown). This suggests that PEG-Au NPs and BP-PEG-Au NPs were not cleared 
from mice during the time period studied, but instead redistributed throughout the body. 
Moreover, renal clearance was not expected since the size of the Au NPs in this study was larger 
than the glomerular filtration system cutoff [51].
The histopathology of various organs and tissues was examined at 2, 14, and 28 days 
after delivering PEG-Au NPs and BP-PEG-Au NPs in wildtype mice, and at 2 and 14 days after 
delivering PEG-Au NPs and BP-PEG-Au NPs in PyMT mice (Fig. 6). There were no apparent 
changes in tissue or cellular morphology, and thus no evidence of tissue level toxicity, in the 
MGs, spleen, and liver due to the accumulation of PEG-Au NPs or BP-PEG-Au NPs at any time 
point compared with untreated controls. PEG-Au NPs and BP-PEG-Au NPs were taken up by 
macrophages in the MGs, spleen, and liver (arrows, Fig. 6), and this accumulation appeared to 
increase with time. Intracellular PEG-Au NPs and BP-PEG-Au NPs appeared to be highly 
concentrated within the cytoplasm but did not appear to enter the nucleus. There has been a 
paucity of data for the long term (weeks) in vivo cytotoxicity of Au NPs at concentrations 
necessary for use as an X-ray contrast agent, particularly for the liver and spleen, which typically 
accumulate the highest concentrations of Au NPs after delivery [25]. Therefore, the results of 
this study aid in filling a gap in the literature and are promising for clinical translation of PEG-
  
Au NPs and BP-PEG-Au NPs given that the MGs and spleen were exposed to a relatively high 
concentration of Au NPs over 28 days (Fig. 5).
The absence of any histological evidence of tissue level toxicity over 28 days exposure to 
relatively high concentrations of Au NPs is promising but warrants further analysis. For 
example, the spleen was exposed to a mass concentration of Au that was approximately ~6000X 
greater than that previously shown to result in no cellular or genetic toxicity [50,52]. 
Additionally, the mass concentration of Au in the liver was much lower than the MGs and spleen 
but was still ~2X greater than that previously reported to cause acute liver toxicity and genetic 
changes indicative of an immune response [50,52,53]. Therefore, the results of this study must be 
followed with more detailed cellular and molecular level analyses. Nonetheless, the results of 
this study are significant due to providing a relatively long-term evaluation of the in vivo 
biodistribution and cytoxocity of Au NPs at a dose suitable for use an X-ray contrast agent, 
which is significantly greater than doses typically used to study the in vitro and in vivo toxicity 
of Au NPs [25].
4. Conclusions
The addition of BP ligands to PEGylated Au NPs (BP-PEG-Au NPs) resulted in five-fold 
greater binding affinity for targeting HA µcals, as expected, due to the strong binding affinity of 
BP ligands for calcium. Therefore, BP-PEG-Au NPs were able to target HA µcals in vivo after 
intramammary delivery, which enabled contrast-enhanced radiographic detection of µcals in both 
normal and radiographically dense mammary tissues similar to previous results for BP-Au NPs, 
while PEG-Au NPs did not. The addition of a PEG spacer between the BP targeting ligand and 
Au NP surface enabled improved in vivo clearance. PEG-Au NPs and BP-PEG-Au NPs were 
cleared from all MGs and control MGs, respectively, within 24-48 h after intramammary 
  
delivery, while BP-Au NPs were not. PEGylated Au NPs were slowly cleared from MGs by 
lymphatic drainage and accumulated in the spleen. Histopathology revealed uptake of PEG-Au 
NPs and BP-PEG-Au NPs by macrophages in the spleen, liver, and MGs; there was no evidence 
of toxicity due to the accumulation of NPs in organs and tissues compared with untreated 
controls for up to 28 days after delivery.
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Tables
Table 1: The mean (± standard deviation) NP diameter, hydrodynamic diameter, zeta potential, 
number of PEG molecules per Au NP (PEG/Au NP), number of BP molecules per Au NP 
(BP/Au NP), and number of BP molecules per Au NP surface area (BP/nm2) for PEG-Au NPs, 
BP-PEG-Au NPs, BP-Au NPs, and Au NPs dispersed in DI water. Groups not connected by the 
same superscript letter exhibited statistically significant differences (p < 0.05, Tukey).
Group
NP 
Diameter 
(nm)
Hydrodynamic 
Diameter (nm)
Zeta 
Potential 
(mV)
PEG/Au 
NP
BP/Au 
NP BP/nm
2
  
n/a = not applicable; 1BP/Au NP and BP/nm2 for PEG-Au NPs were measured to be 43 (14) and 
0.08 (0.01), respectively, which reflected the level of background noise in ICP-OES 
measurements rather than a negligible presence of BP.
Table 2: Binding constants for PEG-Au NPs, BP-PEG-Au NPs, BP-Au NPs, and Au NPs 
adsorbed onto HA crystals in DI water determined by non-linear least squares regression of 
Langmuir adsorption isotherms, where Vmax is the maximum surface binding (mg Au/g HA), 
Vmax* is the maximum surface binding normalized to the specific surface area of HA crystals 
(mg Au/m2 HA), Vmax# is the maximum number of Au NPs bound per surface area of HA crystals 
(#/µm2 HA), and R2 is the correlation coefficient for the regression. The 95% confidence interval 
for Vmax is shown in square brackets.
Figure Captions
Fig. 1. Au NPs were surface functionalized with either (a) monofunctional thiol-terminated PEG 
or (b) heterobifunctional thiol-PEG-COOH which was conjugated to alendronate to provide BP 
ligands for targeting HA µcals. Size distributions measured by TEM (physical diameter) and 
DLS (hydrodynamic diameter) were similar for both (a) PEG-Au NPs and (b) BP-PEG-Au NPs. 
Moreover, PEG-Au NPs and BP-PEG-Au NPs were both spherical and monodispersed, as shown 
in representative TEM micrographs.
Fig. 2. The colloidal stability of (a) PEG-Au NPs and (b) BP-PEG-Au NPs in physiologically 
relevant media, including DI water, PBS, and 10% FBS, showing the hydrodynamic diameter 
measured by DLS at 0, 2, and 7 days and the SPR peak measured by UV-vis spectroscopy at 0 
and 7 days. Error bars show one standard deviation of the mean hydrodynamic diameter (n = 3 
PEG-Au 
NPs 13.1 (1.3)
ab 30.9 (2.2)a -7.2 (2.3)a 965 (240)a n/a1 n/a1
BP-PEG-
Au NPs 12.6 (1.6)
a 33.4 (1.6)b -17.0 (2.8)b 902 (443)a 2500 (1064)a 4.9 (0.7)
a
BP-Au 
NPs 
[31,32]
13.2 (0.9)b 43.5 (1.9)c -11.2 (1.8)c n/a 1845 (405)b 3.5 (0.3)
b
Au NPs 
[30,32] 13.4 (1.2)
b 19.3 (0.3)d -25.2 (1.9)d n/a n/a n/a
Group Vmax (mg/g) Vmax* (mg/m2) Vmax# (#/µm2) R2
PEG-Au NPs 2.1 [1.2, 2.9] 0.4 17 0.62
BP-PEG-Au NPs 9.8 [8.8, 10.9] 1.7 86 0.96
BP-Au NPs [30] 7.7 [6.9, 8.6] 1.4 65 0.95
Au NPs [30] 0.4 [0.2, 0.5] 0.1 3 0.75
  
samples/group/time point). Error bars not shown lie within the data point. *p < 0.05 vs. all other 
groups and time points, Tukey. A gray reference line is shown at 527 nm for comparison of SPR 
peaks in UV-vis spectra.
Fig. 3. Binding isotherms and representative SEM micrographs of PEG-Au NPs and BP-PEG-Au 
NPs adsorbed onto HA crystals in DI water. Error bars show one standard deviation of the mean 
(n = 3 samples/group/time point). Error bars not shown lie within the data point. Experimental 
data were modeled as a Langmuir isotherm (Eq. 1) using non-linear least squares regression 
(lines) and the maximum surface binding constants are reported in Table 2. BP-PEG-Au NPs 
exhibited significantly greater binding affinity to HA crystals compared with PEG-Au NPs, as 
expected due to the high binding affinity of BP ligands for calcium ions on HA crystal surfaces.
Fig. 4. The X-ray attenuation (HU) measured in vivo from 3D CT reconstructions for HA µcals 
compared with negative, contralateral controls in (a,b) wildtype and (c,d) PyMT mice exhibiting 
radiographically dense mammary tissue before (0 h) and longitudinally at 3, 6, 24, and 48 h after 
intramammary delivery of (a,c) PEG-Au NPs and (b,d) BP-PEG-Au NPs. Error bars show one 
standard deviation of the mean (n = 5 mice/group). *p < 0.05 vs. 0 h, Tukey. **p < 0.05 µcal vs. 
control, paired t-test. Note that a differential contrast (ΔHU) of at least 30 HU has been 
suggested to be necessary for visibly apparent enhanced-contrast in CT [38,39]. Representative 
2D grayscale CT image projections show HA µcals within 4L MGs (arrows) compared with 
negative, contralateral controls in 4R MGs (arrowheads), before (0 h) and 48 h after delivering 
PEG-Au NPs and BP-PEG-Au NPs. BP-PEG-Au NPs enabled contrast-enhanced detection of 
µcals in both normal (wildtype) and radiographically dense (PyMT) mammary tissues, while 
PEG-Au NPs did not. PEG-Au NPs and BP-PEG-Au NPs were cleared from all MGs and control 
MGs, respectively, within 24-48 h after delivery.
Fig. 5. The biodistribution of Au measured within organs, tissues, and µcals in wildtype mice at 
2, 14, and 28 days after intramammary delivery of (a) PEG-Au NPs and (b) BP-PEG-Au NPs, 
and in PyMT mice exhibiting radiographically dense mammary tissue at 2 days after 
intramammary delivery of (a) PEG-Au NPs and (b) BP-PEG-Au NPs. Error bars show one 
standard deviation of the mean (n = 3/group/time point). PEG-Au NPs and BP-PEG-Au NPs 
cleared from MGs to the surrounding skin and peritoneum, and accumulated in the spleen more 
than the liver and kidneys.
Fig. 6. Representative transmitted light optical micrographs of histological sections prepared 
from the MGs, spleen and liver of (a) wildtype mice and (b) PyMT mice exhibiting 
radiographically dense mammary tissue before (untreated) and 14 days after intramammary 
delivery of PEG-Au NPs and BP-PEG-Au NPs. Representative micrographs at 2 and 28 days are 
available in Figure 6S as supplementary content. Arrows highlight PEG-Au NPs and BP-PEG-
Au NPs (black in color) taken up by macrophages. No changes were apparent in the cell or tissue 
morphology between treated (PEG-Au NPs and BP-PEG-Au NPs) and untreated tissues for up to 
28 days after delivery, which suggests there was no cytoxicity. Normal ductal structures are 
shown in wildtype mice, while PyMT mice exhibited hyperplastic epithelium surrounding ductal 
structures.
Statement of Significance
  
Au NP imaging probes and therapeutics are commonly surface functionalized with PEG and/or 
high affinity targeting ligands for delivery. However, direct comparisons of PEGylated Au NPs 
with and without a targeting ligand, or ligand-targeted Au NPs with and without a PEG spacer, 
on in vivo targeting efficiency, biodistribution, and clearance are limited. Therefore, the results 
of this study are important for the rationale design of targeted NP imaging probes and 
therapeutics, including the translation of BP-PEG-Au NPs which enable improved sensitivity and 
specificity for the radiographic detection of abnormalities (e.g., µcals) in women with dense 
breast tissue.
